Nurix bolsters leadership; plus Lynch named Xilio chairman, Edgewise, BioXCel, Catabasis, Catalyst and more
Nurix Therapeutics Inc. has announced a slew of leadership changes including Gwenn Hansen’s promotion to CSO from SVP of research, and Hans van Houte’s promotion to CFO from SVP of finance. The targeted protein degradation company, which raised $120 million in its fourth venture round in March, also hired Michael Lotze as chief cellular therapy officer and Robert Brown as VP of clinical development. Lotze was vice chair of research in the department of surgery at the University of Pittsburgh Medical Center. Brown was clinical team lead at Allogene Therapeutics Inc. (NASDAQ:ALLO) (see “Nurix raises $120M”).
Tumor-activated immunotherapy play Xilio Therapeutics Inc. has named Daniel Lynch as chairman. He is a strategic adviser at Third Rock Ventures and chairs bluebird bio Inc. (NASDAQ:BLUE), Surface Oncology Inc. (NASDAQ:SURF), Blueprint Medicines Corp. (NASDAQ:BPMC), Translate Bio Inc. (NASDAQ:TBIO) and SpringWorks Therapeutics Inc. (NASDAQ:SWTX). Xilio raised $100.5 million in a March series B (see “Xilio to deploy $100M B round”). ...